In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Research Technology Ltd.

Executive Summary

CRT is the technology transfer arm of Cancer Research UK, the largest cancer charity in the UK and the biggest single funding body for cancer research projects in Europe. The organization's primary remit is commercializing the IP generated by the £175 million ($274 million) of research funding that Cancer Research UK provides each year.

You may also be interested in...



Cancer Research Technology Ltd.: Biopharma's Gateway to Cancer-Focused Academic Research

Cancer Research Technology - the technology transfer arm of Cancer Research UK, the world's largest charity - has long moved beyond simply commercializing and managing the IP generated by the half billion in research funding provided by Cancer Research UK to five core research institutes across the UK, as well as to researchers at dozens of other universities and organizations. CRT has a growing, 85-strong in-house drug discovery capability which is being expanded with the help of a five-year, £7 million ($11 million) grant from Cancer Research UK - and it's this that lured in AstraZeneca and another industry collaborator, Cephalon.

Venture Philanthropy: The New Venture Capital?

Non-profit organizations' growing support for industry drug development does more than fill a funding gap. It brings disease-knowledge, patient-access and an understanding of the end-market that few traditional VCs can offer.

Antisoma Takes Refuge With Roche

Roche could easily have swallowed cash-poor Antisoma whole. But the Swiss group has instead bought rights to the UK biotech's entire clinical portfolio, hoping thereby to preserve Antisoma's creativity--rather like it has done with Genentech.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

AG020237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel